Joaquin Duato - Johnson Johnson Chairman

JNJ Stock  EUR 147.00  0.18  0.12%   

Chairman

Mr. Joaquin Boix Duato is the Vice Chairman Executive Committee of the Company since 2018.
Age 56
Tenure 6 years
Duato joined the Company in 1989 with JanssenFarmaceutica S.A. and in 1997 became Managing Director of JanssenCilag S.p.A. . In 2000, he led Ortho Biotech Europe before relocating to the United States in 2002 to serve as Vice President, and, in 2005, President of Ortho Biotech Inc. In 2008, he was named Company Group Chairman, OrthoClinical Diagnostics, and in 2009, Company Group Chairman, Pharmaceuticals, where he oversaw pharmaceutical product launches and the major therapeutic franchises in Canada, the United States and Latin America. In 2011, he was named Worldwide Chairman, Pharmaceuticals, responsible for the global commercial businesses of the Janssen Pharmaceutical Companies, including functional support for the research & development organizations. In April 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals.
Johnson Johnson (JNJ) is traded on Berlin Exchange in Germany and employs 33 people.

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman of the Board, Chief Executive Officer
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Marillyn Hewson, Independent Director
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
Michael Ullmann, Executive Vice President, General Counsel
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
D Davis, Independent Director
Hubert Joly, Independent Director
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Anne Mulcahy, Lead Independent Director
Mary Beckerle, Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group
Mark McClellan, Independent Director
Charles Prince, Independent Director
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Mark Weinberger, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Johnson Stock

When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Johnson Stock refer to our How to Trade Johnson Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.